Basidiolipids from Agaricus are novel immune adjuvants

被引:13
作者
Jennemann, R
Bauer, BL
Bertalanffy, H
Selmer, T
Wiegandt, H
机构
[1] Univ Marburg, Fachbereich Biol, Marburg, Germany
[2] Univ Marburg, Zentrum Operat Med 1, Neurochirurg Klin, Marburg, Germany
[3] Univ Marburg, Inst Physiol Chem, D-35043 Marburg, Germany
关键词
D O I
10.1016/S0171-2985(99)80076-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The primary aim of the present study was to compare the immune adjuvanticity of two different groups of glycolipids, i.e., the newly discovered basidiolipids from Basidiomycete mushrooms (Bl-1, Bl-2, Bl-3, and Bl-4), and saponin fractions from Quillaja saponaria. The basidiolipids, though with differential effectiveness of the Bl-components, stimulated the expression of serum immune globulins in mice that recognized co-injected antigens, bovine serum albumin (BSA) or a keyhole-limper hemocyanin-ganglioside Gfpt1 conjugate (KLH-Gfpt1), respectively. The immune adjuvanticity of the basidiolipids was comparable to that of acidic (QAS2, QAS5, QAS10), and novel neutral (QNS1, QNS2, QNS3) saponin compounds isolated and purified from Quillaja saponaria bark bulk material. Basidiolipids, as well as, the Q. saponin fractions were only marginally antigenic. MPL-A, by contrast, a comparable immune adjuvant, stimulated the expression of specific antibodies that recognized this glycophospholipid. Different from the Q. saponins with restricted toxicity, the basidiolipids displayed no toxic or hemolytic properties.
引用
收藏
页码:277 / 289
页数:13
相关论文
共 15 条
[1]   Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis [J].
Fujimiya, Y ;
Suzuki, Y ;
Oshiman, K ;
Kobori, H ;
Moriguchi, K ;
Nakashima, H ;
Matumoto, Y ;
Takahara, S ;
Ebina, T ;
Katakura, R .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 46 (03) :147-159
[2]   ADJUVANTS FOR HUMAN VACCINES - CURRENT STATUS, PROBLEMS AND FUTURE-PROSPECTS [J].
GUPTA, RK ;
SIBER, GR .
VACCINE, 1995, 13 (14) :1263-1276
[3]   ADJUVANTS - A BALANCE BETWEEN TOXICITY AND ADJUVANTICITY [J].
GUPTA, RK ;
RELYVELD, EH ;
LINDBLAD, EB ;
BIZZINI, B ;
BENEFRAIM, S ;
GUPTA, CK .
VACCINE, 1993, 11 (03) :293-306
[4]  
HELLING F, 1994, CANCER RES, V54, P197
[5]  
Ito H, 1997, ANTICANCER RES, V17, P277
[6]   Novel glycoinositolphosphosphingolipids, basidiolipids, from Agaricus [J].
Jennemann, R ;
Bauer, BL ;
Bertalanffy, H ;
Geyer, R ;
Gschwind, RM ;
Selmer, T ;
Wiegandt, H .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 259 (1-2) :331-338
[7]  
Jennemann R, 1996, J BIOCHEM-TOKYO, V119, P378
[8]   SPECIFIC IMMUNIZATION USING KEYHOLE LIMPET HEMOCYANIN-GANGLIOSIDE CONJUGATES [J].
JENNEMANN, R ;
GNEWUCH, C ;
BOSSLET, S ;
BAUER, BL ;
WIEGANDT, H .
JOURNAL OF BIOCHEMISTRY, 1994, 115 (06) :1047-1052
[9]   CD1d-restricted and TCR-mediated activation of V(alpha)14 NKT cells by glycosylceramides [J].
Kawano, T ;
Cui, JQ ;
Koezuka, Y ;
Toura, I ;
Kaneko, Y ;
Motoki, K ;
Ueno, H ;
Nakagawa, R ;
Sato, H ;
Kondo, E ;
Koseki, H ;
Taniguchi, M .
SCIENCE, 1997, 278 (5343) :1626-1629
[10]  
KENSIL CR, 1991, J IMMUNOL, V146, P431